Mostrar el registro sencillo del ítem

dc.contributor.authorFernández Pombo, Antía*
dc.contributor.authorSánchez Iglesias, Sofía*
dc.contributor.authorCastro Pais, Ana Isabel*
dc.contributor.authorGinzo-Villamayor, M.J.*
dc.contributor.authorCobelo-Gómez, S.*
dc.contributor.authorPrado-Moraña, T.*
dc.contributor.authorDíaz-López, E.J.*
dc.contributor.authorCasanueva Freijo, Felipe *
dc.contributor.authorLoidi Fernández de Trocóniz, Lourdes*
dc.contributor.authorAraujo Vilar, David *
dc.date.accessioned2025-09-12T11:44:57Z
dc.date.available2025-09-12T11:44:57Z
dc.date.issued2023
dc.identifier.citationFernández-Pombo A, Sánchez-Iglesias S, Castro-Pais AI, Ginzo-Villamayor MJ, Cobelo-Gómez S, Prado-Moraña T, et al. Natural history and comorbidities of generalised and partial lipodystrophy syndromes in Spain. Frontiers in Endocrinology. 2023;14.
dc.identifier.issn1664-2392
dc.identifier.otherhttps://portalcientifico.sergas.gal//documentos/657f1ac93ea324404509bf7b
dc.identifier.urihttp://hdl.handle.net/20.500.11940/21770
dc.description.abstractThe rarity of lipodystrophies implies that they are not well-known, leading to delays in diagnosis/misdiagnosis. The aim of this study was to assess the natural course and comorbidities of generalised and partial lipodystrophy in Spain to contribute to their understanding. Thus, a total of 140 patients were evaluated (77.1% with partial lipodystrophy and 22.9% with generalised lipodystrophy). Clinical data were collected in a longitudinal setting with a median follow-up of 4.7 (0.5-17.6) years. Anthropometry and body composition studies were carried out and analytical parameters were also recorded. The estimated prevalence of all lipodystrophies in Spain, excluding Köbberling syndrome, was 2.78 cases/million. The onset of phenotype occurred during childhood in generalised lipodystrophy and during adolescence-adulthood in partial lipodystrophy, with the delay in diagnosis being considerable for both cohorts. There are specific clinical findings that should be highlighted as useful features to take into account when making the differential diagnosis of these disorders. Patients with generalised lipodystrophy were found to develop their first metabolic abnormalities sooner and a different lipid profile has also been observed. Mean time to death was 83.8 ± 2.5 years, being shorter among patients with generalised lipodystrophy. These results provide an initial point of comparison for ongoing prospective studies such as the ECLip Registry study.
dc.description.sponsorshipThis study was supported by the Instituto de Salud Carlos III (grant PI22/00514) and co-funded by the European Union, and an intramural grant from the Xunta de Galicia, ED431B 2020/37. AF-P receives funding from the Fundacion Alfonso Martin Escudero. SS-I was awarded a Research Fellowship, granted by the Asociacion Espanola de Familiares y Afectados de Lipodistrofias (AELIP).
dc.languageeng
dc.rightsAttribution 4.0 International (CC BY 4.0)*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subject.meshAdolescent *
dc.subject.meshHumans *
dc.subject.meshAdult *
dc.subject.meshLipodystrophy, Congenital Generalized *
dc.subject.meshSpain *
dc.subject.meshProspective Studies *
dc.subject.meshLipodystrophy *
dc.subject.meshSyndrome *
dc.titleNatural history and comorbidities of generalised and partial lipodystrophy syndromes in Spain
dc.typeArtigo
dc.authorsophosFernández-Pombo, A.; Sánchez-Iglesias, S.; Castro-Pais, A.I.; Ginzo-Villamayor, M.J.; Cobelo-Gómez, S.; Prado-Moraña, T.; Díaz-López, E.J.; Casanueva, F.F.; Loidi, L.; Araújo-Vilar, D.
dc.identifier.doi10.3389/fendo.2023.1250203
dc.identifier.sophos657f1ac93ea324404509bf7b
dc.journal.titleFrontiers in Endocrinology*
dc.organizationServizo Galego de Saúde::Áreas Sanitarias (A.S.) - Complexo Hospitalario Universitario de Santiago::Endocrinoloxía e nutrición
dc.organizationServizo Galego de Saúde::Áreas Sanitarias (A.S.) - Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS)::Endocrinoloxía e nutrición
dc.organizationServizo Galego de Saúde::Áreas Sanitarias (A.S.) - Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS)
dc.organizationServizo Galego de Saúde::Áreas Sanitarias (A.S.) - Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS)::Endocrinoloxía e nutrición
dc.organizationFundación Pública Galega de Medicina Xenómica
dc.organizationServizo Galego de Saúde::Áreas Sanitarias (A.S.) - Complexo Hospitalario Universitario de Santiago::Endocrinoloxía e nutrición
dc.relation.projectIDInstituto de Salud Carlos III [PI22/00514]
dc.relation.projectIDEuropean Union
dc.relation.projectIDXunta de Galicia [ED431B 2020/37]
dc.relation.projectIDFundacion Alfonso Martin Escudero
dc.relation.projectIDAsociacion Espanola de Familiares y Afectados de Lipodistrofias (AELIP)
dc.relation.publisherversionhttps://doi.org/10.3389/fendo.2023.1250203
dc.rights.accessRightsopenAccess*
dc.subject.keywordAS Santiago
dc.subject.keywordCHUS
dc.subject.keywordAS Santiago
dc.subject.keywordIDIS
dc.subject.keywordAS Santiago
dc.subject.keywordIDIS
dc.subject.keywordAS Santiago
dc.subject.keywordIDIS
dc.subject.keywordFPGMX
dc.subject.keywordAS Santiago
dc.subject.keywordCHUS
dc.typefidesArtículo Científico (incluye Original, Original breve, Revisión Sistemática y Meta-análisis)
dc.typesophosArtículo Original
dc.volume.number14


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Attribution 4.0 International (CC BY 4.0)
Excepto si se señala otra cosa, la licencia del ítem se describe como Attribution 4.0 International (CC BY 4.0)